SingleHealing & Recovery

Teriparatide 10mg

Synthetic bioactive fragment of parathyroid hormone (1-34) investigated for its distinct bone-building anabolic properties.

Mechanism

Intermittently binds the PTH1 receptor to selectively stimulate osteoblast-driven bone formation over osteoclast-mediated bone resorption via the cAMP/PKA and Wnt pathways.

Dosing

The documented baseline reference dose in research protocols is 20 mcg administered once daily.

Reconstitution

Reconstituting a 10 mg vial with 2 mL of bacteriostatic water creates a final solution concentration of 5 mg/mL (5,000 mcg/mL).

Storage

Store the unmixed powder protected from light under refrigeration, and keep the reconstituted solution strictly at 2 to 8 °C without freezing.

Mix & measure Teriparatide 10mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure Teriparatide 10mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration5.00mg/mL

Draw volume0.004mL

On the syringe0.400units

Total doses in vial: 500.0

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Baseline Reference	20 mcg once daily	0.004 mL (~0.4 units)
High Trial Reference	40 mcg once daily	0.008 mL (~0.8 units)
Extended Level	80 mcg once daily	0.016 mL (~1.6 units)

Reconstitution Steps

1
Sterilize the rubber stoppers of both the teriparatide vial and bacteriostatic water vial using sterile alcohol swabs and allow them to completely dry.
2
Draw exactly 2 mL of bacteriostatic water into a sterile mixing syringe.
3
Introduce the needle into the teriparatide vial at a slight angle, directing the fluid slowly down the glass wall rather than forcing it straight onto the lyophilized powder.
4
Allow the mixture to stand undisturbed for roughly 30 seconds to initiate passive dissolution.
5
Gently rotate or roll the vial between your hands until the solution is fully transparent and clear; avoid vigorous shaking.
6
Inspect visually for unmixed particles before placing the reconstituted vial into refrigeration between 2 and 8 °C.

Supplies Needed

Peptide Vial

Lyophilized powder containing 10 mg of purified Teriparatide PTH(1-34)

Insulin Syringes (U-100)

Calibrated precision syringes used to measure small volumetric aliquots

Bacteriostatic Water

Sterile diluent (2 mL required) used to solubilize the peptide for research use

Alcohol Swabs

70% isopropyl wipes for sterilizing vial tops and work surfaces prior to dilution

Why researchers study it

Bone mineral density expansion

Skeletal fracture healing dynamics

Pulsatile anabolic versus continuous catabolic PTH signaling

Osteoblastogenesis and Wnt pathway activation

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

Teriparatide represents the biologically functional amino-terminal 1-34 fragment of human parathyroid hormone. While clinically recognized under the trade name Forteo for managing advanced skeletal fragility, laboratory research models examine the peptide's unique capability to drive new bone formation rather than solely inhibiting resorption. In experimental settings, this 34-amino-acid peptide serves as the primary benchmark for studying targeted bone mineral accrual and skeletal tissue repair. A key scientific paradox inherent to parathyroid hormone signaling is its dual response profile: steady, constant exposure provokes catabolic bone demineralization, whereas transient, pulsatile spikes induce a robust anabolic cascade. Because pharmaceutical applications operate at a minute microgram threshold, milligram-scale research vials are primarily leveraged for in vitro cellular models or handling and concentration assays, requiring precise dilution protocols to manage the vast potency contained within single lyophilized units. Preclinical and laboratory evaluations frequently examine teriparatide for accelerated fracture union, osseointegration adjacent to orthopedic implants, and the activation of osteoblast precursor pathways. Research documentation mandates stringent laboratory handling and volumetric awareness, given that standard syringes struggle to accurately isolate the microgram-level fractions represented within multi-milligram bulk vials.

References

1.Neer et al., New England Journal of Medicine, 2001 — Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
2.Vahle et al., Toxicologic Pathology, 2004 — Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose
3.Gilsenan et al., Journal of Bone and Mineral Research, 2021 — Teriparatide did not increase adult osteosarcoma incidence in a 15-year US postmarketing surveillance study
4.Gilsenan et al., Osteoporosis International, 2018 — The Forteo Patient Registry linkage to multiple state cancer registries
5.Chen et al., Biochemical Pharmacology, 2021 — Parathyroid hormone and its related peptides in bone metabolism